Regulatory milestone in sickle cell treatment
On December 8, 2023, the U.S. Food and Drug Administration (FDA) approved two cell-based gene therapies for sickle cell disease (SCD): Casgevy and Lyfgenia. In the same action, Casgevy became the first FDA-approved therapy that uses CRISPR/Cas9 genome editing. Both products are approved for patients 12 years of age and older.
How Casgevy works
Casgevy uses a patient’s own blood-forming stem cells (autologous hematopoietic stem cells). These cells are edited ex vivo with CRISPR/Cas9 and then returned to the patient after myeloablative conditioning. The goal is to increase fetal hemoglobin (HbF), which helps reduce red-cell sickling and improves oxygen delivery.
Clinical outcomes reported by the FDA
The FDA described evidence from an ongoing single-arm, multicenter study in adolescents and adults with severe SCD and recurrent vaso-occlusive crises (VOCs). A total of 44 patients received Casgevy. Among 31 patients with sufficient follow-up, 29 (93.5%) were free from severe VOC episodes for at least 12 consecutive months during the 24-month follow-up window. FDA also reported successful engraftment across treated patients, with no graft failure or graft rejection in that dataset.
Published trial evidence
Peer-reviewed publication of exagamglogene autotemcel (exa-cel; Casgevy) in the New England Journal of Medicine reported results from the CLIMB SCD-121 study. The report included 44 treated participants and showed that 29 of 30 evaluable participants were free from VOCs for at least 12 consecutive months; all 30 evaluable participants were free from hospitalizations for VOCs for at least 12 consecutive months. Differences in evaluable denominators reflect dataset timing and follow-up cutoffs.
Safety and implementation limits
The FDA noted adverse events commonly associated with conditioning and transplant processes, including low blood counts, mucositis, nausea, pain, febrile neutropenia, headache, and itching. Because treatment requires specialized manufacturing, transplant-center coordination, and high-intensity conditioning, access and long-term monitoring remain central implementation challenges.
Why this matters for public health
Sickle cell disease affects about 100,000 people in the United States and more than 20 million people worldwide, according to NHLBI resources. Gene-editing therapy introduces a new curative-intent pathway beyond conventional supportive care, but the field still needs broader access models, durable long-term outcome data, and safer conditioning strategies.
